4D Molecular Therapeutics, Inc. Lease, Cost
4D Molecular Therapeutics, Inc. (FDMT) reported Lease, Cost of $2.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. lease, cost for the quarter ending 2026-06-30 was $2.02M, a 1.51% increase year-over-year.
- 4D Molecular Therapeutics, Inc. lease, cost for the quarter ending 2026-03-31 was $2.02M, a 4.13% decline year-over-year.
- 4D Molecular Therapeutics, Inc. lease, cost for the quarter ending 2025-12-31 was $2.01M, a 5.72% increase year-over-year.
- 4D Molecular Therapeutics, Inc. lease, cost for the quarter ending 2025-09-30 was $2.02M, a 42.91% increase year-over-year.
- 4D Molecular Therapeutics, Inc. lease, cost for fiscal 2025 was $8.14M, a 47.31% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. lease, cost for fiscal 2024 was $5.53M, a 36.86% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. lease, cost for fiscal 2023 was $4.04M, a 6.32% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. lease, cost for fiscal 2022 was $3.80M, a 7.11% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.02M 10-Q · filed 2026-08-13 | $4.04M 10-Q · filed 2026-08-13 | $6.06M derived: sum of 3 quarters · filed 2026-08-13 | $8.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.02M 10-Q · filed 2026-05-07 | $4.03M derived: sum of 2 quarters · filed 2026-05-07 | $6.05M derived: sum of 3 quarters · filed 2026-05-07 | $8.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $4.03M derived: sum of 2 quarters · filed 2026-03-18 | $6.02M derived: sum of 3 quarters · filed 2026-08-13 | $8.14M 10-K · filed 2026-03-18 |
| 2025-09-30 | $2.02M 10-Q · filed 2025-11-10 | $4.01M derived: sum of 2 quarters · filed 2026-08-13 | $6.13M 10-Q · filed 2025-11-10 | $8.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.99M 10-Q · filed 2026-08-13 | $4.11M 10-Q · filed 2026-08-13 | $6.00M derived: sum of 3 quarters · filed 2026-08-13 | $7.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.11M 10-Q · filed 2026-05-07 | $4.01M derived: sum of 2 quarters · filed 2026-05-07 | $5.42M derived: sum of 3 quarters · filed 2026-05-07 | $6.47M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $3.31M derived: sum of 2 quarters · filed 2026-03-18 | $4.37M derived: sum of 3 quarters · filed 2026-03-18 | $5.53M 10-K · filed 2026-03-18 |
| 2024-09-30 | $1.41M 10-Q · filed 2025-11-10 | $2.46M derived: sum of 2 quarters · filed 2025-11-10 | $3.62M 10-Q · filed 2025-11-10 | $4.52M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.05M 10-Q · filed 2025-08-11 | $2.10M 10-Q · filed 2025-08-11 | $3.11M derived: sum of 3 quarters · filed 2025-08-11 | $4.12M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.05M 10-Q · filed 2025-05-08 | $2.06M derived: sum of 2 quarters · filed 2025-05-08 | $3.07M derived: sum of 3 quarters · filed 2025-05-08 | $4.08M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.02M derived: sum of 2 quarters · filed 2025-02-28 | $3.03M derived: sum of 3 quarters · filed 2025-02-28 | $4.04M 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.01M 10-Q · filed 2024-11-13 | $2.02M derived: sum of 2 quarters · filed 2024-11-13 | $3.03M 10-Q · filed 2024-11-13 | $4.16M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.01M 10-Q · filed 2024-08-08 | $2.02M 10-Q · filed 2024-08-08 | $3.15M derived: sum of 3 quarters · filed 2024-08-08 | $4.11M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.18M 10-Q · filed 2024-05-09 | $2.14M derived: sum of 2 quarters · filed 2024-05-09 | $3.10M derived: sum of 3 quarters · filed 2024-05-09 | $4.04M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $956.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.91M derived: sum of 2 quarters · filed 2024-02-29 | $2.86M derived: sum of 3 quarters · filed 2024-02-29 | $3.80M 10-K · filed 2024-02-29 |
| 2022-09-30 | $957.00K 10-Q · filed 2023-11-09 | $1.90M derived: sum of 2 quarters · filed 2023-11-09 | $2.84M 10-Q · filed 2023-11-09 | $3.78M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $943.00K 10-Q · filed 2023-08-09 | $1.95M 10-Q · filed 2023-08-09 | $2.82M derived: sum of 3 quarters · filed 2023-08-09 | $3.74M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $964.00K 10-Q · filed 2023-05-11 | $1.88M derived: sum of 2 quarters · filed 2023-05-11 | $2.80M derived: sum of 3 quarters · filed 2023-05-11 | $3.73M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $916.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.83M derived: sum of 2 quarters · filed 2023-03-15 | $2.77M derived: sum of 3 quarters · filed 2023-03-15 | $3.54M 10-K · filed 2023-03-15 |
| 2021-09-30 | $917.00K 10-Q · filed 2022-11-08 | $1.85M derived: sum of 2 quarters · filed 2022-11-08 | $2.63M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $938.00K 10-Q · filed 2022-08-11 | $1.71M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $760.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |